BioWorld - Thursday, April 2, 2026

BioWorld Science

Feb. 3, 2016

View Archived Issues

Novartis reviews key milestones of fourth quarter 2015

Read More

Optogenetic modulation of response by controlling Ca2+ flow into cells: NIR-activated immunotherapy

Read More

Research Council of Norway awards funding to Bionor and Nordic Nanovector

Read More

Corvus initiates phase I/Ib study of CPI-444 in advanced cancer

Read More

Companies investigate approaches to tackle Zika virus

Read More

Shionogi updates progress of third quarter of fiscal 2015

Read More

Targovax submits a study protocol for ONCOS-102 trial to the regulatory authorities in Spain

Read More

AbbVie updates pipeline progress of fourth quarter 2015

Read More

The Medicines Company completes divestiture of hemostasis portfolio to Mallinckrodt

Read More

Recurrent genetic alterations identified in low-grade neuroepithelial tumors

Read More

Ligand licenses use of OmniAb platform to Tizona Therapeutics

Read More

Endomorphin analogues show potent analgesia with low side-effect profile

Read More

Repurposing RXR agonist HX-630: Possible new treatment for Cushing's disease?

Read More

Abbott to acquire Alere

Read More

Ono Pharmaceutical recaps highlights of third quarter of fiscal 2015

Read More

Neurocrine initiates phase II study of valbenazine in pediatric patients with Tourette syndrome

Read More

LEO Pharma and arGEN-X select cell line for manufacture of antibody against skin inflammation

Read More

Trimesta shows no benefit in relapsing-remitting MS in women

Read More

Versartis reports results from extension study of somavaratan in children with GHD

Read More

FDA issues CRL regarding Telesta Therapeutics' MCNA

Read More

Tagrisso approved in E.U. for EGFR-mutant NSCLC

Read More